贝伐单抗可有效治疗CNV
[align=center][font=Times New Roman][size=3][color=seagreen]Bevacizumab shows efficacy against CNV associated with pseudoxanthoma elasticum[/color][/size][/font] [/align][align=center][font=Times New Roman][size=2][color=red]贝伐单抗可以有效治疗弹性假黄瘤引起的脉络膜新生血管[/color][/size][/font][/align][font=Times New Roman][size=2][color=blue]Intravitreal bevacizumab appears effective both functionally and morphologically for treating patients with choroidal neovascularization secondary to pseudoxanthoma elasticum, a study by researchers in Germany found.[/color][/size][/font][font=Times New Roman][size=2][color=blue][/color][/size][/font]
[font=Times New Roman][size=2][color=blue]"Best recovery can be achieved in eyes with disease that has not progressed too far and if treatment is initiated at the earliest point possible," the authors said. [/color][/size][/font]
[font=Times New Roman][size=2][color=blue][/color][/size][/font]
[font=Times New Roman][size=2][color=blue]Robert P. Finger, MD, and colleagues at University of Bonn and Hospital Saarbrücken evaluated outcomes for 16 eyes of 15 patients treated with 1.5-mg intravitreal injections of Avastin (bevacizumab, Genentech). All patients had active CNV secondary to pseudoxanthoma elasticum. [/color][/size][/font]
[font=Times New Roman][size=2][color=blue][/color][/size][/font]
[font=Times New Roman][size=2][color=blue]Patients received additional injections based on disease activity, such as a vision loss of five letters or one line, persistent leakage[color=magenta]（渗漏）[/color] or persistent macular edema. They received an average of 2.4 injections, according to the study. [/color][/size][/font]
[font=Times New Roman][size=2][color=blue][/color][/size][/font]
[font=Times New Roman][size=2][color=blue]Patients averaged 53 years of age, and follow-up averaged 8 months. [/color][/size][/font]
[font=Times New Roman][size=2][color=blue][/color][/size][/font]
[font=Times New Roman][size=2][color=blue]Best corrected visual acuity averaged 20/100 at baseline. After the first injection, BCVA improved to average 20/63 and remained stable through final follow-up. [/color][/size][/font]
[font=Times New Roman][size=2][color=blue][/color][/size][/font]
[font=Times New Roman][size=2][color=blue]Central retinal thickness significantly decreased, from 252 µm at baseline to 214 µm at final follow-up, the investigators reported. [/color][/size][/font]
[font=Times New Roman][size=2][color=blue][/color][/size][/font]
[font=Times New Roman][size=2][color=blue]They found that patients who had only mild morphological changes in the central macula had a significantly better improvement than patients who had evident morphological changes in the central macula, according to the study, published in the April issue of [i]British Journal of Ophthalmology[/i].[/color][/size][/font]
[size=3][color=purple][b]这是一篇关于抗VEGF治疗CNV的研究摘要：贝伐单抗对CNV有效；用药后最佳视力明显提高，黄斑水肿明显减轻；越早治疗效果越理想。[/b][/color][/size]
[size=3][color=purple][b][biggrin] [/b][/color][/size]
[[i] 本帖最后由 xiaotianyuzi 于 2008-4-19 22:58 编辑 [/i]]
页:
[1]
